Abstract
Purpose To compare the neuropsychological functioning of breast cancer patients with invasive cancer and noninvasive cancer prior to adjuvant treatment. Patients and Methods Breast cancer patients (N = 132) with invasive (Stages 1–3, N = 110, age = 54.1 ± 8.1) or noninvasive (Stage 0, N = 22, age = 55.8 ± 8.0) disease completed a battery of neuropsychological and psychological instruments following surgery but prior to initiation of chemotherapy, radiation or hormonal therapy. Matched healthy controls (N = 45, age = 52.9 ± 10.0) completed the same battery of instruments. For the patients, data on menstrual status, type of surgery, time of general anesthesia, CBC and platelets, nutritional status (B12 and folate), and thyroid function were collected. Results Comparison of mean neuropsychological test scores revealed that all groups scored within the normal range; however, patients with Stage 1–3 cancer scored significantly lower than healthy controls on the Reaction Time domain (p = 0.005). Using a definition of lower than expected cognitive performance that corrected for misclassification error, Stage 1–3 patients were significantly (p = 0.002) more likely to be classified as having lower than expected overall cognitive performance (22%) as compared to Stage 0 patients (0%) and healthy controls (4%). No differences were observed between patients classified as having lower than expected cognitive performance compared to those classified as normal performance on measures of depression, anxiety, fatigue, menstrual status, surgery/anesthesia or any of the blood work parameters. Conclusion Patients with Stage 1–3 breast cancer were more likely to be classified as having lower than expected cognitive performance prior to adjuvant treatment as compared to Stage 0 patients and healthy controls, although correction for misclassification error produced a lower rate than previously reported.
Similar content being viewed by others
References
Wieneke MH, Dienst ER (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4:61–66
van Dam FS, Schagen SB, Muller MJ et al (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218
Schagen SB, van Dam FS, Muller MJ et al (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650
Brezden CB, Phillips KA, Abdolell M et al (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701
Tchen M, Juffs HG, Downie FP et al (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183
Castellon SA, Ganz PA, Bower JE et al (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–969
Ahles TA, Saykin AJ, Furstenberg CT et al (2002) Neuropsychological impact of standard-dose chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493
Tannock IF, Ahles TA, Ganz PA, van Dam FS (2004) Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22:2233–2239
Wefel JS, Lenzi R, Theriault RL et al (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299
Schilling V, Jenkins V, Morris R et al (2005) The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational study. Breast 14:142–150
Mar Fan HG, Houede-Tchen N, Yi QL et al (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23:8025–8032
Jenkins V, Shilling V, Deutsch G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834
Wefel JS, Lenzi R, Theriault R et al (2004) Chemobrain in breast carcinoma? A prologue. Cancer 101:466–475
Cimprich B, So H, Ronis DL et al (2005) Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology 14:70–78
Ahles TA, Saykin AJ (2002) Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 3(Suppl 3):S84–S90
Rasmussen LS, Johnson T, Kuipers HM et al (2003) Does anaesthesia cause postoperative cognitive dysfunction? A randomized study of regional versus general anaesthesia in 438 elderly adults. Acta Anaesthesiol Scand 47:260–266
Johnson T, Monk T, Rasmussen LS et al (2002) Postoperative cognitive dysfunction in middle-aged patients. Anesthesiology 96:1351–1357
Wagner LI, Butt Z, Sabatino T (2005) Prechemotherapy cognitive function in patients with cancer. ASCO Education Book, pp 392–397
Moretti R, Torre P, Antonello RM et al (2004) Vitamin B12 and folate depletion in cognition: a review. Neurol India 52:310–318
Shilling V, Jenkins V, Trapala IS (2006) The (mis)classification of chemo-fog—methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 95:125–129
Wilkinson GS (1993) WRAT3 Administration Manual. Wide Range, Inc., Wilmington, DE
The Psychological Corporation (1999) Wechsler abbreviated scale of intelligence. The Psychological Corporation, San Antonio, TX
Delis DC, Kaplan E, Kramer JH (2001) Delis-kaplan executive function system. The Psychological Corporation, San Antonio, TX
Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California verbal learning test. 2nd edn. Adult Version Manual. The Psychological Corporation, San Antonio, TX
The Psychological Corporation (1997) WAIS-III wechsler adult intelligence scale, IIIrd edn. WMS-III Wechsler Memory Scale, IIIrd edn Updated Technical Manual. The Psychological Corporation, San Antonio, TX
Fischer JS, Jak AJ, Kniker JE et al (2001) Multiple Sclerosis Functional Composite (MSFC) Administration and scoring manual. National Multiple Sclerosis Society, New York
Lafayette Instrument (1989) Grooved pegboard: instruction/owner’s manual. Lafayette Instrument, Lafayette, IN
Gordon M, McClure FD, Aylward GP (1986) The gordon diagnostic system instruction manual and interpretive guide. Gordon Systems Inc., Dewitt, NY
Radloff LS (1977) The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–392
Plutchick R, Conte HR (1989) Self-report scales for the measurement of depression. Psychiatr Ann 19:367–371
Spielberger CD, Gorsuch RL, Lushene RG (1983) Manual for the state-trait anxiety inventory for adults. Mind Garden, Palo Alto, CA
Hann DM, Jacobsen PB, Martin SC et al (1997) Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer 5:44–52
Seidenberg M, Haltiner A, Taylor MA et al (1994) Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol 16:93–104
Graybill FA (1976) Theory and application of the linear model. Duxbury, Boston, pp 231–236
Turk DC, Okifuji A (1994) Detecting depression in chronic pain patients: adequacy of self-reports. Behav Res Ther 32:9–16
Altaha R, Abraham J (2003) Paraneoplastic neurologic syndrome associated with occult breast cancer: a case report and review of the literature. Breast J 9:417–419
Georgian-Smith D, Ellis GK, Kraft GH (2003) Amphiphysin paraneoplastic syndrome: a delayed diagnosis of breast carcinoma. Breast J 9:316–318
Heflin LH, Meyerowitz BE, Hall P et al (2005) Cancer as a risk factor for cognitive deficits and dementia. J Natl Cancer Inst 97:854–856
Wefel JS, Meyers CA (2005) Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst 97:788–789
Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7:192–201
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to virchow? Lancet 357:539–545
de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37
Wilson CJ, Finch CE, Cohen HJ (2002) Cytokines and cognition: the case for a head-to-toe inflammatory paradigm. JAGS 50:2041–2056
Maier SF, Watkins LR (2003) Immune-to-central nervous system communication and its role in modulating pain and cognition: implications for cancer and cancer treatment. Brain Behav Imm 17:S125–S131
Cleeland CS, Bennett GJ, Dantzer R et al (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97:2919–2925
Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11:1513–1530
Blasiak J, Arabski M, Krupa R et al (2004) Basal oxidative and alkylative DNA damage, DNA repair efficacy, and mutagen sensitivity in breast cancer. Mutat Res 554:139–148
Migliore L, Fontana I, Trippi F et al (2005) Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26:567–573
Rolig RL, McKinnon PJ (2000) Linking DNA damage and neurodegeneration. Trends Neurosci 23:417–424
Acknowledgement
Supported by grants (R01 CA87845 and R01 CA101318) from the Office of Cancer Survivorship, National Cancer Institute, Bethesda, MD.
Author information
Authors and Affiliations
Corresponding author
Additional information
This manuscript represents original research that has not been published previously. The authors have no financial disclosures to make regarding this study. All methods and procedures were approved by the Institutional Review Board of Dartmouth Medical School and all participants provided informed consent.
Rights and permissions
About this article
Cite this article
Ahles, T.A., Saykin, A.J., McDonald, B.C. et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110, 143–152 (2008). https://doi.org/10.1007/s10549-007-9686-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9686-5